ReviewMediators of inflammation2012
Update on the role of cannabinoid receptors after ischemic stroke.
Review in Mediators of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Trial
- Cannabinoid Effect and Safety in Spasticity Following Stroke: A Double-Blind Randomized Placebo-Controlled Study.Frontiers in neurology · 2022Article
- The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.International journal of molecular sciences · 2021Review
- Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome?BMJ case reports · 2021Article
- β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19.Frontiers in pharmacology · 2021Article
- Association between recent cannabinoid use and acute ischemic stroke.Neurology. Clinical practice · 2020Article
- Cannabinoid CB1 receptor agonist ACEA alleviates brain ischemia/reperfusion injury via CB1-Drp1 pathway.Cell death discovery · 2020Article
- A Systematic Review of Essential Oils and the Endocannabinoid System: A Connection Worthy of Further Exploration.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- Modulation of the Endocannabinoid System Following Central Nervous System Injury.International journal of molecular sciences · 2019Review
- Oral Ingestion ofCannabis and cannabinoid research · 2018Article
- Bidirectional Microglia-Neuron Communication in Health and Disease.Frontiers in cellular neuroscience · 2018Review
- Brain cannabinoid receptor 2: expression, function and modulation.Acta pharmacologica Sinica · 2017Review
- β-Caryophyllene/Hydroxypropyl-β-Cyclodextrin Inclusion Complex Improves Cognitive Deficits in Rats with Vascular Dementia through the Cannabinoid Receptor Type 2 -Mediated Pathway.Frontiers in pharmacology · 2017Article
- Cannabis, Cannabinoids, and Cerebral Metabolism: Potential Applications in Stroke and Disorders of the Central Nervous System.Current cardiology reports · 2015Review
- Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.Molecular neurodegeneration · 2015Review
- Article
- Time-Dependent Protection of CB2 Receptor Agonist in Stroke.PloS one · 2015Article
- What we know and do not know about the cannabinoid receptor 2 (CB2).Seminars in immunology · 2014Review
- Neuroprotection in stroke: past, present, and future.ISRN neurology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabinoids are considered as key mediators in the pathophysiology of inflammatory diseases, including atherosclerosis. In particular, they have been shown to reduce the ischemic injury after acute cardiovascular events, such as acute myocardial infarction and ischemic stroke. These protective and anti-inflammatory properties on peripheral tissues and circulating inflammatory have been demonstrated to involve their binding with both selective cannabinoid type 1 (CB₁ and type 2 (CB₂) transmembrane receptors. On the other hands, the recent discoveries of novel different classes of cannabinoids and receptors have increased the complexity of this system in atherosclerosis. Although only preliminary data have been reported on the activities of novel cannabinoid receptors, several studies have already investigated the role of CB₁ and CB₂ receptors in ischemic stroke. While CB₁ receptor activation has been shown to directly reduce atherosclerotic plaque inflammation, controversial data have been shown on neurotransmission and neuroprotection after stroke. Given its potent anti-inflammatory activities on circulating leukocytes, the CB₂ activation has been proven to produce protective effects against acute poststroke inflammation. In this paper, we will update evidence on different cannabinoid-triggered avenues to reduce inflammation and neuronal injury in acute ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.